noxR3, a Novel Gene from Mycobacterium tuberculosis, Protects Salmonella typhimurium from Nitrosative and Oxidative Stress

by Ruan, Jia, St. John, Gregory, Ehrt, Sabine, Riley, Lee, Nathan, Carl
Published 1999

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clin...

by Emery, Paul, van Hoogstraten, Hubert, Thangavelu, Karthinathan, Mangan, Erin, St John, Gregory, Verschueren, Patrick
Published in ACR Open Rheumatol (2020)

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis

by Kovalenko, Pavel, Paccaly, Anne, Boyapati, Anita, Xu, Christine, St John, Gregory, Nivens, Michael C., Davis, John D., Rippley, Ronda, DiCioccio, A. Thomas
Published in CPT Pharmacometrics Syst Pharmacol (2020)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase...

by Genovese, Mark C., Fleischmann, Roy, Kivitz, Alan, Lee, Eun-Bong, van Hoogstraten, Hubert, Kimura, Toshio, St John, Gregory, Mangan, Erin K., Burmester, Gerd R.
Published in Arthritis Res Ther (2020)

Mycobacterium tuberculosis expresses methionine sulfoxide reductases A and B that protect from killing by nitrite and hypochlorite

by Lee, Warren L., Gold, Benjamin, Darby, Crystal, Brot, Nathan, Jiang, Xiuju, de Carvalho, Luiz Pedro S., Wellner, Daniel, St. John, Gregory, Jacobs, William R., Nathan, Carl
Published 2009

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheuma...

by Pappas, Dimitrios A, St John, Gregory, Etzel, Carol J, Fiore, Stefano, Blachley, Taylor, Kimura, Toshio, Punekar, Rajeshwari, Emeanuru, Kelechi, Choi, Jeannie, Boklage, Susan, Kremer, Joel M
Published in Ann Rheum Dis (2021)

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension

by Burmester, Gerd R, Strand, Vibeke, Rubbert-Roth, Andrea, Amital, Howard, Raskina, Tatiana, Gómez-Centeno, Antonio, Pena-Rossi, Claudia, Gervitz, Leon, Thangavelu, Karthinathan, St John, Gregory, Boklage, Susan, Genovese, Mark C
Published in RMD Open (2019)

Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years’ follow-up

by Fleischmann, Roy, Genovese, Mark C, Lin, Yong, St John, Gregory, van der Heijde, Désirée, Wang, Sheldon, Gomez-Reino, Juan Jose, Maldonado-Cocco, Jose Antonio, Stanislav, Marina, Kivitz, Alan J, Burmester, Gerd R
Published in Rheumatology (Oxford) (2020)

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment

by Genovese, Mark C, van der Heijde, Désirée, Lin, Yong, St John, Gregory, Wang, Sheldon, van Hoogstraten, Hubert, Gómez-Reino, Juan José, Kivitz, Alan, Maldonado-Cocco, José Antonio, Seriolo, Bruno, Stanislav, Marina, Burmester, Gerd R
Published in RMD Open (2019)

Data‐Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry

by Curtis, Jeffrey R., Weinblatt, Michael, Saag, Kenneth, Bykerk, Vivian P., Furst, Daniel E., Fiore, Stefano, St John, Gregory, Kimura, Toshio, Zheng, Shen, Bingham, Clifton O., Wright, Grace, Bergman, Martin, Nola, Kamala, Charles‐Schoeman, Christina, Shadick, Nancy
Published in Arthritis Care Res (Hoboken) (2021)